UNASSIGNED: @entity413 lowering therapy in type 1 and type 2 @entity6 is often associated with hypoglycemic events. To avoid this, @entity413 lowering therapies need to be developed that support the hypoglycemic defense mechanisms. Such development needs a tool for evaluating counterregulatory mechanisms in vivo. A sustained glucagon release during @entity4053 is of most importance to hypoglycemic defense mechanisms. We have therefore developed a graded hyperinsulinemic hypoglycemic clamp in @entity19 and used it to evaluate counterregulatory glucagon dynamics. @entity413 was clamped at narrow intervals aiming at 2.5, 3.5, 4.5, and 6.0 mmol/L. Glucagon levels were increased during @entity4053 in a @entity413 -dependent way with a glucagon counterregulatory threshold between 3.5 and 4.0 mmol/L. Modelling the @entity413 -glucagon relationship using a hyperbolic curve with the equation: plasma glucagon = -4.20 + 90.79/blood @entity413 showed high correlation. When comparing this method to the insulin tolerance test as an approach to study glucagon dynamics in vivo, we found that the graded clamp more efficiently evoked a robust, predictable, glucagon response with considerably less variation in blood @entity413 . In conclusion, we have developed a tool for the study of in vivo glucagon dynamics during @entity4053 in @entity19 and demonstrated a hyperbolic @entity413 -counterregulatory glucagon relationship.

Deciphering the Hypoglycemic Glucagon Response: Development of a Graded Hyperinsulinemic Hypoglycemic Clamp Technique in Female XXXX .

@entity19 :: ('10090', 'Species') :: ['mice'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose', 'Glucose'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity4053 :: ('MESH:D007003', 'Disease') :: ['hypoglycemia']
@entity19 :: (10090,Species) :: ['Mice']
